ELDN Eledon Pharmaceuticals Inc.

3.74
-0.26  -7%
Previous Close 4
Open 3.91
52 Week Low 3.7
52 Week High 22.91
Market Cap $51,450,387
Shares 13,756,788
Float 13,755,780
Enterprise Value $-42,368,613
Volume 90,761
Av. Daily Volume 124,990
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
AT-1501
Type 1 diabetes (islet cell transplantation)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
AT-1501
Amyotrophic Lateral Sclerosis
Phase 2a
Phase 2a
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
AT-1501
Islet cell transplantation
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
AT-1501
IgA nephropathy (IgAN)
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
AT-1501
Kidney transplant rejection
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences:

    Event:LifeSci Partners Corporate Access Event (January 5-7, 2022)
    Format:1x1 Meetings
      

    To register for the LifeSci Partners Corporate Access Event, please use the following link: here.

    Event:H.C. Wainwright BIOCNNECT Virtual Conference (January 10-13, 2022)
    Format:Available on Demand Presentation for registered attendees

    IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences:

    Event:LifeSci Partners Corporate Access Event (January 5-7, 2022)
    Format:1x1 Meetings
      

    To register for the LifeSci Partners Corporate Access Event, please use the following link: here.

    Event:H.C. Wainwright BIOCNNECT Virtual Conference (January 10-13, 2022)
    Format:Available on Demand Presentation for registered attendees via the H.C. Wainwright site and 1x1 Meetings
      

    If you are interested in arranging a one-on-one meeting request for the H.C. Wainwright BIOCNNECT Virtual Conference, please contact your H.C. Wainwright representative, or contact Corey Davis at the address below.

    About Eledon Pharmaceuticals and AT-1501

    Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com.

    Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

    Investor Contact

    Corey Davis, Ph.D.         

    LifeSci Advisors         

    212-915-2577                 



    Primary Logo

    View Full Article Hide Full Article
  2. Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022

    Received Investigational New Drug ("IND") clearance from the FDA for AT-1501 in islet cell transplantation in the U.S.

    Announced renal transplantation research collaboration with CareDx, Inc.

    Initiated AT-1501 monotherapy non-human primate renal transplant study; topline data expected 1H 2022

    Conference call today at 4:30 PM ET

    IRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS…

    Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022

    Received Investigational New Drug ("IND") clearance from the FDA for AT-1501 in islet cell transplantation in the U.S.

    Announced renal transplantation research collaboration with CareDx, Inc.

    Initiated AT-1501 monotherapy non-human primate renal transplant study; topline data expected 1H 2022

    Conference call today at 4:30 PM ET

    IRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS), today reported its third quarter 2021 operating and financial results.

    "We made significant progress across our three therapeutic areas: transplantation focusing on kidney and islet cell transplantation, autoimmunity focused on IgA Nephropathy (IgAN), and neurodegeneration focusing on ALS," stated David-Alexandre C. Gros, M.D., Chief Executive Officer. "In ALS, we completed enrollment in the first three cohorts of our phase 2 study and anticipate completing enrollment in the fourth and final cohort by year-end. In renal transplantation, we are in the process of opening our first clinical site in Canada and our non-human primate study in the U.S. is well underway. We recently announced IgAN as the next indication for development of AT-1501 and are still on track to initiate a Phase 2 trial by the end of this year. Finally, we received IND clearance for AT-1501 to initiate a clinical trial for the prevention of islet cell rejection in the U.S. We remain focused on continued execution across our three therapeutic areas in 2021 and building momentum as we prepare for multiple data readouts in 2022."

    "In addition, we recently announced our research collaboration with CareDx, the leader in precision medicine for transplant patients and caregivers," said Steven Perrin, Ph.D., President and Chief Scientific Officer of Eledon. "This multi-year and multi-trial collaboration provides us with access to CareDx's best-in-class technologies for our renal transplantation studies. Our partner's extensive experience with biomarkers and predictive algorithms will allow us to gather important insights on the potential for product differentiation and long-term allograft survival rates as we advance AT-1501 through clinical development."

    Third Quarter 2021 and Recent Corporate Developments

    • Received a "No Objection" Letter from Health Canada, allowing Eledon to initiate a Canadian clinical trial of AT-1501 for the prevention of kidney transplant rejection.
    • Announced selection of IgAN as next indication for clinical development of AT-1501; initiation of Phase 2 study expected by year-end.
    • Completed enrollment of the first three cohorts of a Phase 2 study of AT-1501 in ALS; fourth and final cohort enrollment is nearing completion with full enrollment expected by year-end.
    • Initiated preclinical renal transplant study evaluating AT-1501 monotherapy in at least four non-human primates.
    • Announced renal transplant research collaboration with CareDx providing Eledon access to CareDx's best-in-class biomarker and predictive algorithm technologies.
    • Received IND clearance from the U.S. Food & Drug Administration for AT-1501 in islet cell transplantation in the United States.
    • Presented data at the 2021 Northeast Amyotrophic Lateral Sclerosis Consortium and the International Pancreas and Islet Transplantation World Congress.

    Upcoming Anticipated Milestones

    • Q4 2021: initiation of Phase 1b clinical trial of AT-1501 in kidney transplantation.
    • Q4 2021: initiation of Phase 2 clinical trial of AT-1501 in IgAN.
    • 1H 2022: topline data from Phase 2 trial of AT-1501 in ALS.
    • 1H 2022: completion of non-human primate study with AT-1501.
    • 2H 2022: initial data from Phase 1b trial of AT-1501 in kidney transplantation.
    • 2H 2022: initial data from Phase 2 trial of AT-1501 in IgAN.
    • 2022: initial data from Phase 2 trial of AT-1501 in islet cell transplantation.

    Financial Results for the Three Months Ended September 30, 2021

    • The company reported a net loss of $9.8 million, or $0.66 per share, for the three months ended September 30, 2021, compared to a net loss of $6.1 million, or $5.51 per share, for the same period in 2020.
    • Research and development expenses were $7.7 million for the three months ended September 30, 2021, compared to $0.6 million for the comparable period in 2020, an increase of $7.1 million. The increase in research and development spend primarily reflects clinical and formulation costs associated with increased activity for our lead asset AT-1501.
    • General and administrative expenses were $2.8 million for the three months ended September 30, 2021, compared to $3.7 million for the comparable period in 2020, a decrease of $0.9 million.
    • The company had approximately $94.0 million in cash and cash equivalents as of September 30, 2021, compared to $114.2 million in cash and cash equivalents as of December 31, 2020. The Company believes that it has sufficient financial resources to fund operations as currently planned well into 2023.

    Conference Call

    Eledon will hold a conference call today, November 11, 2021 at 4:30 pm Eastern Time to discuss third quarter results. The dial-in numbers are 877-407-9039 for domestic callers and 201-689-8470 for international callers. The conference ID is 13723561. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.eledon.com. The webcast will be archived on the website following the completion of the call.

    About Eledon Pharmaceuticals and AT-1501

    Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com.

    Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company's capital resources and ability to finance planned clinical trials, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "looks forward," "could," "may," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company's capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company's actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Contact:

    Corey Davis, Ph.D.

    LifeSci Advisors, LLC



    212.915.2577

    Source: Eledon Pharmaceuticals

     
    ELEDON PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except share data)

    (Unaudited)
           
      September 30,

    2021
      December 31,

    2020
     
    ASSETS        
    Current assets:        
    Cash and cash equivalents $94,041  $114,195 
    Prepaid expenses and other current assets  1,517   1,435 
    Total current assets  95,558   115,630 
    Operating lease asset, net  222   138 
    Goodwill  48,648   48,648 
    In-process research and development  32,386   32,386 
    Other assets  356   383 
    Total assets $177,170  $197,185 
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current liabilities:        
    Accounts payable $1,598  $1,366 
    Current operating lease liability  177   144 
    Accrued expenses and other liabilities  2,271   973 
    Total current liabilities  4,046   2,483 
    Deferred tax liabilities  2,331   4,106 
    Non-current operating lease liability  45    
    Total liabilities  6,422   6,589 
             
    Commitments and contingencies (Note 5)        
             
    Stockholders' equity:        
    Series X1 non-voting convertible preferred stock, $0.001 par value, 515,000 shares authorized; 108,070 shares issued and outstanding at September 30, 2021 and December 31, 2020      
    Series X preferred stock, $0.001 par value, 10,000 shares authorized; 6,204 and no shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively      
    Common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2021 and December 31, 2020; 14,306,788 and 15,160,397 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively  14   15 
    Additional paid-in capital  276,827   270,974 
    Accumulated deficit  (106,093)  (80,393)
    Total stockholders' equity  170,748   190,596 
    Total liabilities and stockholders' equity $177,170  $197,185 
             



     
    ELEDON PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In thousands, except share and per share data)

    (Unaudited)
           
      For the Three Months

    Ended September 30,
      For the Nine Months

    Ended September 30,
     
      2021  2020  2021  2020 
    Operating expenses                
    Research and development $7,658  $615  $17,553  $3,095 
    General and administrative  2,848   3,731   9,929   6,730 
    Restructuring expense     1,802      2,292 
    Total operating expenses  10,506   6,148   27,482   12,117 
    Loss from operations  (10,506)  (6,148)  (27,482)  (12,117)
    Other income, net  3   4   7   39 
    Warrant inducement expense           (4,829)
    Loss before income tax benefit  (10,503)  (6,144)  (27,475)  (16,907)
    Income tax benefit  686      1,775    
    Net loss and comprehensive loss $(9,817) $(6,144) $(25,700) $(16,907)
    Net loss per share, basic and diluted $(0.66) $(5.51) $(1.73) $(16.81)
    Weighted-average common shares outstanding, basic and diluted  14,815,852   1,114,133   14,820,822   1,006,008 
                     



    Primary Logo

    View Full Article Hide Full Article
  3. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced today that David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon, will deliver a presentation at the CareDx virtual Transplant Innovation Day which is taking place tomorrow, November 5, from 12:00 – 1:00 PM ET, during the American Society of Nephrology (ASN) Kidney Week 2021. Dr. Gros will discuss the potential of using AT-1501 in organ and cellular transplantation as well as the recently announced…

    IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced today that David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon, will deliver a presentation at the CareDx virtual Transplant Innovation Day which is taking place tomorrow, November 5, from 12:00 – 1:00 PM ET, during the American Society of Nephrology (ASN) Kidney Week 2021. Dr. Gros will discuss the potential of using AT-1501 in organ and cellular transplantation as well as the recently announced research collaboration between Eledon and CareDx.

    Registration for the Transplant Innovation Day is available here.

    CareDx collaboration

    Eledon previously announced that the company has entered into a collaborative research agreement with CareDx, Inc., a leading precision medicine solutions company. Eledon will utilize CareDx's best-in-class KidneyCare™ suite, including Allosure®, a non-invasive cell free DNA assay transplant surveillance, and iBox®, a technology that provides a prognostic indication of allograft survival, in its upcoming renal transplantation studies. Eledon believes that data gathered from these technologies will provide additional insights on allograft health and survival as AT-1501 advances through clinical development.

    About Eledon Pharmaceuticals and AT-1501

    Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com.

    Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, the use of CareDx products in its trials, and its collaboration with CareDx, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "looks forward," "could," "may," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company's capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company's actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Contact:

    Corey Davis, Ph.D.

    LifeSci Advisors, LLC



    212.915.2577

    Source: Eledon Pharmaceuticals



    Primary Logo

    View Full Article Hide Full Article
  4. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that members of management will be participating in two upcoming virtual investor conferences in November.

    Event:Guggenheim 3rd Annual Neuro/Immunology Conference (November 15-16)
    Format:1x1 Meetings
      
    Event:Jefferies London Healthcare Conference (November 18-19)
    Format:Available on Demand Presentation and 1x1 Meetings
    Date:Thursday, November 18, 2021
    Time:Available on-demand starting at 3:00 AM ET
    Location:

    IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that members of management will be participating in two upcoming virtual investor conferences in November.

    Event:Guggenheim 3rd Annual Neuro/Immunology Conference (November 15-16)
    Format:1x1 Meetings
      
    Event:Jefferies London Healthcare Conference (November 18-19)
    Format:Available on Demand Presentation and 1x1 Meetings
    Date:Thursday, November 18, 2021
    Time:Available on-demand starting at 3:00 AM ET
    Location:webcast link

    Replay Link:

    A replay will be accessible for 90 days following the live session on the Events page of the Investors section on the Company's website at https://ir.eledon.com/events-and-presentations/events.

    If you are interested in arranging a one-on-one meeting virtually on either November 18th or 19th, please contact your Jefferies representative. For more information about the Jefferies London Healthcare Conference, please visit the Jefferies conference website.

    About Eledon Pharmaceuticals and AT-1501

    Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com.

    Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

    Investor Contact

    Corey Davis, Ph.D.         

    LifeSci Advisors         

    212-915-2577                 



    Primary Logo

    View Full Article Hide Full Article
  5. IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that it plans to release financial results for the third quarter ended September 30, 2021 on Thursday, November 11, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 pm ET.

    Conference Call and Webcast Details:
    Thursday, November 11, 2021 at 4:30 PM Eastern Time / 1:30 PM Pacific Time
    Toll Free: 877-407-9039 
    International: 201-689-8470…

    IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that it plans to release financial results for the third quarter ended September 30, 2021 on Thursday, November 11, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 pm ET.

    Conference Call and Webcast Details:

    Thursday, November 11, 2021 at 4:30 PM Eastern Time / 1:30 PM Pacific Time

    Toll Free: 877-407-9039 

    International: 201-689-8470 

    Conference ID: 13723561

    Webcast: https://ir.eledon.com/events-and-presentations/events

    After the live webcast, the event will be archived on Eledon's website for one year.

    About Eledon Pharmaceuticals and AT-1501

    Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com.

    Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.

    Investor Contact:

    Corey Davis, Ph.D.

    LifeSci Advisors, LLC



    212.915.2577

    Source: Eledon Pharmaceuticals



    Primary Logo

    View Full Article Hide Full Article
View All Eledon Pharmaceuticals Inc. News